Does polypharmacy shape dependency transitions in the very old? Findings from the Newcastle 85+ Study

Laurie E. Davies¹, Adam Todd², Louise Robinson¹,†, Andrew Kingston¹,†

¹Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK
²School of Pharmacy, Newcastle University, Newcastle upon Tyne, UK

Address correspondence to: Laurie E. Davies. Email: laurie.davies@newcastle.ac.uk
†Joint senior author

Abstract

Background: helping older people to maintain their independence, and identifying risk factors that compromise this, is of high importance. Polypharmacy is common in the very old (aged ≥ 85) but whether it can shape transitions in dependency in this fastest growing subpopulation is unclear.

Methods: using Newcastle 85+ Study data and multi-state modelling, we investigated the association between each additional medication prescribed and the progression of and recovery from dependency states, over 10 years (age 85–95). Participants were defined as either free from care (independent), requiring care less often than daily (low dependency), or requiring care at regular intervals each day or 24 hourly (medium/high dependency).

Results: each additional medication prescribed was associated with a 10% decreased chance of recovery from low dependence to independence (hazard ratio (HR): 0.90, 95% confidence interval (CI): 0.82–0.99).

Discussion: when a relatively able person visits the GP or clinical pharmacist, careful consideration should be given to whether the potential benefits from adding a new medication outweigh the risk to reduced recovery of independence.

Keywords: polypharmacy, very old, primary care, older people

Key Points

• We investigated whether polypharmacy shapes transitions between dependency states in the very old over 10 years.
• From age 85 to 95, the care requirements for very old people increased substantially.
• Each additional medication prescribed decreased the chance of recovery from low dependence to independence by 10%.

Background

Underpinning functional ability is the autonomous completion of activities of daily living (ADLs), such as shopping, dressing, toileting and bathing, though the number of ADLs that cannot be performed gives little indication of the intensity of social care support an individual requires [1]. A better measure is achieved by combining activities of daily living, continence and cognition, and measuring the time interval between necessary periods of help for these tasks (so-called 'dependency') [1].

Older age is often accompanied by an inability to self-care and live independently (i.e. dependency) [1, 2], and the world’s population is ageing [3]; for example by mid-2045 in the UK, numbers of the very old (aged ≥85 years) will almost double to 3.1 million [4]. The loss of independence can profoundly affect quality of life [5, 6], and increase healthcare use [7], and many high-income countries are contending with how to finance social care to support their ageing populations [8, 9], making preservation of function for older people a public health priority [10].
To help maintain the independence of and/or prevent loss of function of older people, evidence for how risk factors shape transitions in dependency is required for example, and the role of complex multimorbidity has been identified in those aged 85 and over [11]. One possible consequence of multimorbidity is polypharmacy. Polypharmacy is generally understood as the concurrent use of multiple medicines [12] and is common in the very old. For instance, 85 year olds in English primary care are prescribed a median of six medicines, with 65% prescribed at least five medicines [13]. Polypharmacy is thought to be a potential modifier of the disablement process [14], but there is no evidence to quantify whether it can influence dependency transitions in the very old, despite co-occurrence, and potential mechanisms. These include (i) non-adherence leading to the onset or worsening of disabling diseases, and greater total disease, and (ii) cumulative medication side effects affecting cognition, continence status or the self-reported ability to do activities of daily living.

The prevalence of polypharmacy in growing older populations is also likely to rise in the coming years, because of rising multimorbidity [15], whilst the supply of caregivers, who support people with dependency, is expected to decline [16].

All this considered, we aim to examine, for the first time, the association between polypharmacy (defined as the number of prescribed medications) and transitions in dependency in the very old over 10 years using a rich dataset: the Newcastle 85+ Study.

Methods

Design and setting

The Newcastle 85+ Study is a population-based longitudinal study of people who were born in 1921, aged 85 in 2006 when the study began, and permanently registered with a participating general practice in Newcastle or North Tyneside [17]. The study has 10 years of follow-up, and data were collected in two ways over this time: multidimensional health assessments by trained research nurses in participants usual place of residence, inclusive of care homes, at baseline (wave 1), 18 months (wave 2), 36 months (wave 3), 60 months (wave 4) and 120 months (wave 5), and review of general practice medical records at baseline, waves 3, 4 and 5. Study questionnaires and the GP record review proforma are available on the Newcastle 85+ Study website https://research.ncl.ac.uk/85plus/. Full details of the study design and recruitment strategy have been published [17–19], and an overview of study recruitment and retention can be found in Appendix 1 (available in Age and Ageing online). Of the 849 people who were eligible for analyses at baseline, we constructed a measure of dependency on 806 individuals (497 women and 309 men).

Ethical approval

The Newcastle and North Tyneside Local Research Committee One approved the Newcastle 85+ Study (Ref: 06/Q0905/2).

Medication data

A detailed discussion characterising polypharmacy amongst the Newcastle 85+ Study participants has previously been presented [13]. Data on prescribed medications were obtained from general practice medical records and coded according to the British National Formulary [19]. From which polypharmacy was operationalised as a continuous variable, i.e. as a count of the number of prescribed medications, to account for potential nonlinearity within categorical thresholds [20]. Participant reported over-the-counter medications and items such as vaccines, wound-management products and catheter/stoma products were excluded from this analysis (Appendix 2 available in Age and Ageing online) [13].

Definition of dependency

Our measure of dependency comprises four categories based on the time interval between necessary periods of help with activities of daily living, urinary continence and cognition: (i) independent: free from care, (ii) low dependency: requiring help less than daily, (iii) medium dependency: requiring help at regular intervals each day and (iv) high dependency: requiring 24-hour care [1]. The logic statements for classifying participants and the items used are provided in Box 1.

Box 1. Definition of dependency

| High dependency: | MMSE score of less than 10, or having severe or profound urinary incontinence with inability to dress or undress without help, or unable to perform, without help, any of: transfer to/from toilet, or transfer to/from a chair or feeding oneself. |
| Medium dependency: | Unable to perform, without help, any of: transfer to/from bed, dressing and undressing, preparing and cooking a hot meal, taking medication or washing face and hands. |
| Low dependency: | Unable to perform without help, any of: washing all over, shopping for groceries, light housework, heavy housework, managing money or cutting own toenails. |
| Independent: | The remainder of participants were defined as independent (free from care). Participants were classified as missing if they could not be categorised. |
Statistical analysis

Participant characteristics were examined through descriptive statistics. To model transitions in dependency over 10 years, we fitted a multi-state model with four states: independent, low dependency, medium/high dependency and death (Appendix 3 available in Age and Ageing online). Medium- and high-dependency states were collapsed to enable model convergence. Age was used as the temporal metric to mitigate some of the effect of the Markov assumption i.e. that only the current state influences future progression. Survival time was calculated from the date of baseline interview to the date of death or censoring at 120 months (if a participant had taken part in the 10-year follow-up). Models were adjusted in stage as follows:

- Polypharmacy and age (model 1)
- Polypharmacy, age and sex (model 2)
- Polypharmacy, age, sex and years in education (model 3)
- Polypharmacy, age, sex, years in education and multiple long-term conditions (model 4)
- Polypharmacy, age, sex, years in education, multiple long-term conditions and body mass index (model 5).

Covariates (excepting sex and years in education) were treated as time varying. Full details of disease status construction can be found in Appendix 4 (available in Age and Ageing online). Analyses were conducted in R V.4.0.2 using the msm package [21].

Results

Changes in dependency levels between age 85 and 95

By age 95, the proportion of men and women who were independent reduced significantly (age 85: 58% of men, 31% of women; age 95: 23% of men, 5% of women). For women, the greatest increase in care needs was in the proportion with high dependency (requiring 24-hour care) (8% at age 85, 25% by age 95) whilst for men, the greatest increase was for those requiring care at regular intervals throughout the day (12% at age 85 and 27% by age 95) (medium levels of dependency) (Figure 1).

Prevalence of polypharmacy by dependency level

For men and women, median medication counts broadly increase with increased dependency (Table 1).

Multistate model

As shown in Table 2, each additional medication prescribed is associated with a 10% decrease in the chance of recovery from low dependence to independence (HR: 0.90, 95% CI: 0.82–0.99, model 5), but is not significantly associated with (i) the progression of dependency—be it transitions from independence to low dependence (HR: 1.02, 95% CI: 0.97–1.08), independence to medium/high dependence (HR: 0.49, 95% CI: 0.20–1.19), or low to medium/high dependence (HR: 1.03, 95% CI: 0.96–1.10) –, or (ii) recovery from medium/high to low dependence (HR: 1.03, 95% CI: 0.91–1.16) (model 5).

Discussion

Principle findings

From age 85 to 95, the care requirements for very old people increased substantially. Each additional medication prescribed decreased the chance of recovery from low dependence to independence by 10%.

Comparison with existing literature

The decreased chance of reablement associated with each additional prescribed medication at the point of low dependency might reflect cumulative side effects with the potential to affect manual dexterity and balance, such as drowsiness or dizziness. Adverse drug reactions are more common in older people [22, 23] and also increase with the number of prescribed medications for example [24], and such effects can be ascribed to frailty, existing diagnoses or new medical problems [25]. Indeed in this study in the North East, approximately 30% of participants with low dependency were frail at baseline (Appendix 5 available in Age and Ageing online), and multimorbidity is the norm in the very old [26]. Our findings might also stem from non-adherence following rising medication counts [27], leading to the onset or progression of disabling diseases, especially as older people and their family carers often struggle to manage medicines with little or no support [28]. The reason why each additional prescribed medication reduced the chance of recovery from low but not medium or high care needs also reflects the disability hierarchy. Indeed low dependency is the optimal point at which reablement is possible; beyond this, in the very old, the chances of recovery are slim to nothing (Appendix 3 available in Age and Ageing online).

Strengths and limitations

To our knowledge, this is the first study to examine how polypharmacy shapes dependency transitions in the very old, over long-term follow-up, with medication and disease data obtained from general practice medical records as opposed to the less reliable method of self-report [19]. Multistate modelling has previously been used to examine how polypharmacy shapes frailty transitions over time in older community-dwelling men [29], so our analysis extends the existing literature.

However our work has limitations, mainly, we could not isolate the medication classes or combinations that hinder the recovery of independence, and previous research describes medication count as a reductionist measure [30]. Secondly, we could not reliably calculate hazard ratios separately by sex due to the reduced number of transitions, and
there are known differences in prescribing [13] and dependency [2] between very old men and women. Whilst we adjusted for changes in multimorbidity as a count over time, we had no information on disease progression or severity for example, so residual confounding cannot be excluded as is the case with all observational studies. Our results also predate the COVID-19 pandemic. In order to model all transitions that are clinically plausible (for example transitioning from independence to a heightened state of unhealthiness following a catastrophic event), we merged participants with medium or high dependency on the basis of their similar characteristics (i.e. both need intensive levels of care and help with personal care). We could not capture prescribing changes outside of data collection points, which could overlook fluctuations in medication prescription (such as medications prescribed for short-term use). We also cannot confirm whether medications were taken as prescribed; to measure non-adherence, a linked prescribing and dispensing

**Figure 1.** Prevalence of dependency from 85 to 95 years of age.

**Table 1.** Median medication counts by dependency level from 85–95 years of age

| Dependency level | Sample | Baseline (age = 85) | Wave 3 (age = 88.5) | Wave 4 (age = 90) | Wave 5 (age = 95) |
|------------------|--------|---------------------|---------------------|-------------------|-------------------|
| Independent      | All    | 5 (2–7)             | 5 (2.5–7)           | 5 (3–7.25)        | 4 (3–9)           |
|                  | Men    | 5 (3–7)             | 5 (3–7)             | 5 (3–7.5)         | 6.5 (3.25–9.75)   |
|                  | Women  | 4 (2–6)             | 4 (2–6.25)          | 4 (1–7)           | 2 (1.5–4)         |
| Low              | All    | 6 (4–9)             | 6 (4–9.25)          | 7 (4.5–10)        | 8 (5–10)          |
|                  | Men    | 6 (4–8)             | 6 (4–9)             | 7 (4.75–9)        | 7.5 (5.25–9)      |
|                  | Women  | 6 (4–9)             | 6 (5–10)            | 6 (4.5–10)        | 8 (5–10)          |
| Medium           | All    | 8 (5–10)            | 6 (4–9.5)           | 8 (4–11)          | 7 (5–10)          |
|                  | Men    | 7 (5–10)            | 4.5 (3.25–7)        | 4.5 (3–10.25)     | 6 (5–9.5)         |
|                  | Women  | 8 (6–10)            | 7 (5–10)            | 8 (5–10.5)        | 7.5 (6–10.5)      |
| High             | All    | 7 (4.5–9)           | 8 (6–10.5)          | 7 (5–9)           | 6 (5–10)          |
|                  | Men    | 6 (4–9)             | 8 (6–8)             | 8.5 (6.75–9.5)    | 8 (6–9)           |
|                  | Women  | 7 (5–10)            | 8 (6–11)            | 6.5 (5–8.75)      | 6 (5.25–9.5)      |
dataset is believed to be optimal, though such linkage is not routine or straightforward [31]. Finally, whilst waves 1–4 of the Newcastle 85+ Study lay within a five-year time window, the interval between waves four and five was five years—we may therefore have missed transitions in dependency between the ages of 90 and 95.

Implications and conclusion

For very old people with low dependency, each additional medication prescribed is associated with a 10% decrease in their chance of reablement. In the future, absolute numbers of people aged 85 and over with low care needs are projected to increase [2], whilst family care networks (the mainstay of support) [16] are expected to become more fragile for reasons including extended working life, greater female labour market participation and more geographically disparate families [1]. Previous research also suggests that low dependency is the optimal point at which reablement is possible [1].

Older people often emphasise the importance of retaining independence for their quality of life [5], fearing disability and dependency more than death itself [32], and whilst life expectancy in most developed countries has increased over previous decades [33], attention is now focussing more on the quality of those extra years lived [34]. Recent reports also state that older people are prescribed too many medicines [35, 36], for which disease-specific clinical guidelines are one explanation [37].

Our findings therefore suggest that when a relatively able person visits the GP or clinical pharmacist, careful consideration must be given to whether the benefits from adding a new medication outweigh the potential for it to impact the capacity to live independently. Given that interventions at the point of low dependency (or even earlier) have the most chance of slowing down decline [1], our findings also advocate the promotion of physical reconditioning programs for older people with polypharmacy and low care needs, though not during the experience of or before resolution of medication side effects.

In terms of future work, evidence for de-prescribing is building [38, 39], and most older people would be willing to stop their medicines if their doctor deemed it appropriate to do so [40]. Future studies could therefore examine whether deprescribing medication in older people with low dependency promotes the transition to independence. If it does, this group could be targeted for medication reviews with the view to deprescribe if appropriate according to individual patient circumstances. If future studies were to also identify the medication classes that hinder the recovery of independence in the very old, this could focus deprescribing in this age group.

### Supplementary Data: Supplementary data mentioned in the text are available to subscribers in *Age and Ageing* online.

### Data Availability Statement: Data cannot be shared publicly because of data governance, GDPR and contractual arrangements with outside organisations who provide individual level data to the study (NHS Digital). Data are available from the Newcastle 85+ Data Guardians (contact via https://research.ncl.ac.uk/85plus/datarequests/) for researchers who meet the criteria for access to confidential data.

### Acknowledgements: Mortality data were obtained from NHS Digital. We acknowledge the operational support of the North of England Commissioning Support Unit, the National Institute for Health Research Clinical Research Network North East and North Cumbria, local general practitioners and their staff. We thank the research nurses, laboratory technicians, data management and clerical team for their work throughout, as well as many colleagues for their expert advice. Thanks are due especially to the study participants and, where appropriate, their families and carers.

### Declaration of Conflicts of Interest: None.

### Declaration of Sources of Funding: The Newcastle 85+ Study has been funded by the Medical Research Council,
Biotechnology and Biological Sciences Research Council, the Dunhill Medical Trust and the National Institute for Health Research School for Primary Care. Parts of the work have also been funded by the British Heart Foundation, Unilever Corporate Research, Newcastle University, NHS North of Tyne (Newcastle Primary Care Trust). LR is supported by an ‘NIHR Senior Investigator Award scheme’ - reference number NF-SI-0616019594.

This research was funded by the Legal & General Group (research grant to establish the independent Advanced Care Research Centre at University of Edinburgh). The funder had no role in conduct of the study, interpretation or the decision to submit for publication. The views expressed are those of the authors and not necessarily those of Legal & General.

References

1. Kingston A, Wohland P, Wittenberg R et al. Is late-life dependency increasing or not? A comparison of the Cognitive Function and Ageing Studies (CFAS). Lancet 2017; 390: 1676–84.
2. Kingston A, Comas-Herrera A, Jagger C, MODEM project. Forecasting the care needs of the older population in England over the next 20 years: estimates from the Population Ageing and Care Simulation (PACSim) modelling study. Lancet Public Health 2018; 3: e447–55.
3. World Health Organisation. Ageing and Health. 2021 [cited 4 April 2022]. Available from: https://www.who.int/news-room/fact-sheets/detail/ageing-and-health#text=Every%20country%20in%20the%20world%20needs%20to%20take%20a%20

4. Office for National Statistics. National Population Projections: 2020-Based Interim. 2022 [cited 3 March 2022]. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/populationandmigration/populationprojections/bulletins/nationalpopulationprojections/2020basedinterim.
5. Gabriel Z, Bowling A. Quality of life from the perspectives of older people. Ageing Soc 2004; 24: 675–91.
6. Farquhar M. Elderly people’s definitions of quality of life. Soc Sci Med 1995; 41: 1439–46.
7. Ferrucci L, Guralnik JM, Pahor M, Corri MC, Havlik RJ. Hospital diagnoses, medica charges, and nursing home admissions in the year when older persons become severely disabled. JAMA 1997; 277: 728–34.
8. Colombo F, Llena-Nozal A, Mercier J, Tjadens F. Help those of the authors and not necessarily those of Legal &

9. Spiers G, Matthews FE, Moffatt S et al. Does older adults’ use of social care influence their healthcare utilisation? A systematic review of international evidence. Health Soc Care Community 2019; 27: e651–62.
10. World Health Organisation. Active Ageing: A Policy Framework. Geneva: World Health Organisation, 2002.
11. Kingston A, Robinson LA, Duncan R, Jagger C. Facilitators of dependency in the very old: results from the Newcastle 85+ Study. Innov Aging 2019; 3: S242-S. https://doi.org/10.1093/geroni/igz038.906.
12. Duerden M, Avery T, Payne R. Polypharmacy and Medicines Optimisation. Making It Safe and Sound. London: The King’s Fund, 2013.
13. Davies LE, Kingston A, Todd A, Hanratty B. Characterising polypharmacy in the very old: Findings from the Newcastle 85+ Study. PLoS One 2021; 16: e0245648. https://doi.org/10.1371/journal.pone.0245648.
14. Verbrugge L, Jette A. The disablement process. Soc Sci Med 1994; 38: 1–14. https://doi.org/10.1016/0277-9536(94)90294-1.
15. Kingston A, Robinson L, Booth H, Knapp M, Jagger C. MODEM project. Projections of multi-morbidity in the older population in England to 2035: estimates from the Population Ageing and Care Simulation (PACSim) model. Age Ageing 2018; 47: 374–80.
16. Jagger C, Collerton JC, Davies K et al. Capability and dependency in the Newcastle 85+ cohort study. Projections of future care needs. BMC Geriatr 2011; 11: 21. https://doi.org/10.1186/1471-2318-11-21.
17. Davies K, Collerton JC, Jagger C et al. Engaging the oldest old in research: lessons from the Newcastle 85+ study. BMC Geriatr 2010; 10: 64. https://doi.org/10.1186/1471-2318-10-64.
18. Collerton J, Barrack K, Bond J et al. The Newcastle 85+ study: biological, clinical and psychosocial factors associated with healthy ageing: study protocol. BMC Geriatr 2007; 7: 14. https://doi.org/10.1186/1471-2318-7-14.
19. Collerton J, Davies K, Jagger C et al. Health and disease in 85 year olds: baseline findings from the Newcastle 85+ cohort study. BMJ 2009; 339: b4904. https://doi.org/10.1136/bmj.b4904.
20. Davies LE, Kingston A, Todd A, Hanratty B. Is polypharmacy associated with mortality in the very old: findings from the Newcastle 85+ Study. Br J Clin Pharmacol 2022; 88: 2988–95.
21. Jackson C. Multi-state models for panel data: the msm package for R. J Stat Softw 2011; 38: 1–28. https://doi.org/10.18637/jss.v038.i08.
22. Hughes SG. Prescribing for the elderly patient: why do we need to exercise caution? Br J Clin Pharmacol 1998; 46: 531–3.
23. Davies EA, O’Mahony MS. Adverse drug reactions in special populations—the elderly. Br J Clin Pharmacol 2015; 80: 796–807.
24. Nolan L, O’Malley K. Prescribing for the elderly part I: sensitivity of the elderly to adverse drug reactions. J Am Geriatr Soc 1988; 36: 142–9.
25. Tangisuran B, Wright J, Van der Cammen T, Rajkumar C. Adverse drug reactions in elderly: challenges in identification and improving preventative strategies. Age Ageing 2009; 38: 358–9.
26. Salive ME. Multimorbidity in older adults. Epidemiol Rev 2013; 35: 75–83.
27. Vik SA, Maxwell CJ, Hogan DB. Measurement, correlates, and health outcomes of medication adherence among seniors. Ann Pharmacother 2004; 38: 303–12.
28. Maidment I, Huckerby C, Shukla D. Medication management in older people—a hidden burden. Prescriber 2020; 31: 30–3.
29. Jamson KM, Bell JS, Hilmer SN et al. Effects of changes in number of medications and drug burden index exposure on transitions between frailty states and death: the concord health
Findings from the Newcastle 85+ Study

and ageing in men project Cohort study. J Am Geriatr Soc 2016; 64: 89–95.

30. Davies LE, Spiers G, Kingston A, Todd A, Adamson J, Harratty B. Adverse outcomes of polypharmacy in older people: systematic review of reviews. J Am Med Dir Assoc 2020; 21: 181–7.

31. Tibble H, Lay-Flurrie J, Sheikh A et al. Linkage of primary care prescribing records and pharmacy dispensing records in the Salford Lung Study: application in asthma. BMC Med Res Methodol 2020; 20: 303. https://doi.org/10.1186/s12874-020-01184-8.

32. Gore PG, Kingston A, Johnson GR, Kirkwood TBL, Jagger C. New horizons in the compression of functional decline. Age Ageing 2018; 47: 764–8.

33. Christensen K, Doblhammer G, Rau R, Vaupel JW. Ageing populations: the challenges ahead. Lancet 2009; 374: 1196–208.

34. Jagger C, Matthews R, Spiers N et al. Compression or Expansion of Disability? Forecasting Future Disability Levels Under Changing Patterns of Diseases. London: King’s Fund, 2006.

35. Age UK. More harm than good. In: Why More Isn’t Always Better With Older People’s Medicines. London: Age UK, 2019.

36. Department for Health and Social Care. Good for You, Good for Us, Good for Everybody. A Plan to Reduce Overprescribing to Make Patient Care Better and Safer, Support the NHS, and Reduce Carbon Emissions, 2021. nationalarchives.gov.uk/doc/open-government-licence/version/3.

37. Hughes LD, McMurdo MET, Guthrie B. Guidelines for people not for diseases: the challenges of applying UK clinical guidelines to people with multimorbidity. Age Ageing 2013; 42: 62–9.

38. Kutner JS, Blatchford PJ, Taylor DH Jr et al. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial. JAMA Intern Med 2015; 175: 691–700.

39. Sheppard JP, Burt J, Lown M et al. Effect of antihypertensive medication reduction vs usual care on short-term blood pressure control in patients with hypertension aged 80 years and older: the OPTIMISE randomized clinical trial. JAMA 2020; 323: 2039–51.

40. Reeve E, Wiese MD, Hendrix I, Roberts MS, Shakib S. People’s attitudes, beliefs, and experiences regarding polypharmacy and willingness to deprescribe. J Am Geriatr Soc 2013; 61: 1508–14.

Received 8 April 2022; editorial decision 1 August 2022